OptiRTP Deepens Engagement with Evidence-Based Oncology Research Community
OptiRTP Limited is pleased to announce that Sharyn Harper, Chief Operating Officer, has joined the Society for Integrative Oncology (SIO) as a member, with a particular focus on the organisation’s Research Committee.
SIO is the premier multi-disciplinary professional organisation advancing evidence-based, integrative approaches to cancer care, with 599 active members across 44 countries. Its mission is centred on improving outcomes for people affected by cancer, bringing together clinicians, researchers, and healthcare professionals dedicated to advancing the evidence base for integrative oncology interventions.
OptiRTP’s OBST (Optimum Bio Sound Therapy) technology addresses one of oncology’s most persistent clinical challenges: treatment-limiting adverse events that cause patients to discontinue life-extending therapies. Engaging directly with the global research community studying these challenges reflects OptiRTP’s commitment to grounding its technology development in rigorous, evidence-based oncology practice.
“Being part of SIO connects us directly with the researchers and clinicians at the forefront of improving cancer treatment tolerability. That’s precisely the community whose work informs and validates what we’re building at OptiRTP.”
About OptiRTP
OptiRTP is a New Zealand health-technology company developing Optimum Bio Sound Therapy (OBST), a neuromodulation platform registered as an FDA Class I medical device. The platform has delivered over 352,393 therapy hours to more than 1,100 users. www.OptiRTP.com
Media Contact
Sharyn Harper, Chief Operating Officer
sharyn.harper@OptiRTP.com · www.OptiRTP.com
